Proxy Votes Now

Home › Funds › Global X › Global X Aging Population ETF

Global X Aging Population ETF (AGNG) proxy voting record 2025-2026

Fund family: Global X · Filed by Global X Funds (CIK 1432353) · SEC series S000054162

Ticker: AGNG (C000170216)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 999 with, 20 against, 5 abstentions (not counted as with management); 177 items carried no recommendation; 16 split votes are in neither count. Shareholder proposals: 21 FOR, 6 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Global X as a whole

The same two figures as Global X’s manager page (125,623 ballot items across 92 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsGlobal XItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)90.4%84291.0%107,427
Backed environmental and social shareholder proposals at US companiesn/a421.0%2,383

Where this fund voted differently from most Global X funds

Each ballot item this fund voted is set against the votes of the other Global X funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted the same way as most Global X funds on all 243 items where a comparison was possible.

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections6051
Corporate Governance2029
Compensation1263
Capital Structure1120
Audit-related812
Say-on-Pay500
Shareholder Rights and Defenses161
Other Social Issues52
Extraordinary Transactions30
Diversity, Equity, and Inclusion11

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
agilon health, inc.March 17, 2026$4M20
Eli Lilly and CompanyMay 4, 2026$4M102
Merck & Co., Inc.May 26, 2026$4M183
Johnson & JohnsonApril 23, 2026$4M151
Welltower Inc.May 21, 2026$4M110
Regeneron Pharmaceuticals, Inc.June 12, 2026$3M70
AbbVie Inc.May 8, 2026$3M81
Amgen Inc.May 19, 2026$3M151

Notable votes against management

MeetingCompanyProposalFundMgmt
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalForAgainst
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
April 23, 2026Johnson & JohnsonIndependent Board Chair Shareholder proposalForAgainst
May 8, 2026AbbVie Inc.Stockholder proposal - to adopt a policy to require an independent chair Shareholder proposalForAgainst
May 19, 2026Amgen Inc.Stockholder proposal to require an independent board chairman. Shareholder proposalForAgainst
May 5, 2026Bristol-Myers Squibb CompanyShareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposalForAgainst
May 22, 2026Zimmer Biomet Holdings, Inc.Shareholder proposal on Independent Board Chairman. Shareholder proposalForAgainst
April 30, 2026Boston Scientific CorporationStockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting." Shareholder proposalForAgainst
March 31, 2026Dentium Co.,Ltd.Establishment of an Evaluation and Compensation Committee (Shareholder Proposal) Shareholder proposalForAgainst
March 31, 2026Dentium Co.,Ltd.Change the Name of Outside Directors and Expand/Guarantee Their Ratio (Shareholder Proposal) Shareholder proposalForAgainst

Contested meetings

Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.

Search this fund’s votes by company

1,202 ballot items at 94 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Global X Aging Population ETF (AGNG) voted at 94 shareholder meetings of 86 companies, on 1,202 ballot items in all. Where management made a recommendation, the fund followed it on 97.6% of the items and voted against it 20 times. Its most frequent area of disagreement was corporate governance (9 of its votes against management). It voted on 33 shareholder proposals. It voted FOR the board's own proposals less often than Global X's funds as a whole (90.4% against 91.0%). It voted the same way as most Global X funds on every item where a comparison was possible. 1 of its meetings was contested.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Global X’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.